We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Seventeen-Year Monopoly on BRCA Testing Ended

By LabMedica International staff writers
Posted on 01 Jul 2013
Myriad Genetics' (Salt Lake City, UT, USA) 17-year monopoly on BRCA testing for genetic risk for breast, ovarian cancer has come to an end.

According to the IVD market research firm, Kalorama Information (New York, NY, USA) the seven-year dispute surrounding BRCA testing has been a source of many lawsuits since 2006. More...
The recent Supreme Court decision denying Myriad Genetics the monopoly on BCRA testing for genetic risk for breast and ovarian cancer will promote the molecular diagnostics industry.

Myriad earned approximately USD 400 million last year from its molecular tests. The company has shown a brave face, emphasizing that it still has an exclusive patent on cDNA.

Shara Rosen, lead diagnostics analyst for Kalorama Information, said the Court struck a balance in its ruling Thursday: it permitted patents on the synthetic form of genes and on systems but did not allow patents on genes occurring in nature. She continued, "The clear and well-balance ruling left the door open for intellectual property protection and incentives for innovation in genomic disease testing. Patents on diagnostic systems for gene testing remain enforceable. “

Tests aimed a molecular target for use in clinical decision-making will produce much faster revenue growth than traditional IVD tests, according to Kalorama Information, that said tests are a 5.2 billion dollar market and will grow 8% each year to 7.6 billion by 2017. Ms. Rosen notes that since 1984, the US Patent and Trademark Office had issued more than 40,000 patents related to genes and it is estimated that about 25% of human genes have been patented. These patents are now invalid. That could open up huge opportunities in genetic disease research and the genetic testing for innumerable diseases.

Kalorama Information's latest report discussed the issues around the Myriad gene patent dispute in length. The report provides estimates of markets and market segments and profiles hundreds of competitors in the market.

Related Links:
Myriad Genetics
Kalorama Information




New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.